cms.bioaccessla.com

Tag: Latin America

  • Radiopharmaceutical Trials In Latin America: Designing Logistics Around Half-Life, Handoffs, And Site Readiness

    Radiopharmaceutical Trials in Latin America: Designing Logistics Around Half-Life, Handoffs, and Site Readiness

    Radiopharmaceutical and radioligand therapies are expanding rapidly, and many sponsors are now looking to Latin America for faster startup, experienced investigators, and access to oncology patient populations. But radiopharma is unforgiving: the physics of radioactive decay turns logistics into a core part of trial design.

    This article focuses on an external knowledge gap we often see in early-stage planning: teams design protocols as if supply behaves like conventional biologics. In radiopharma, half-life, handoffs, and site readiness should be treated as first-order design constraints—especially when operating across borders.

    1) Start with the supply chain reality: isotope generation is often the bottleneck

    A common misconception is that the primary constraint in radiotherapeutics is clinical site availability. In reality, the historically limiting step is often radioisotope generation. Many isotopes rely on specialized production routes and third-party suppliers, and the manufacturing ecosystem is still evolving.

    Planning implication for Latin America: before selecting countries and sites, lock down a realistic isotope supply and production model, including contingency plans for supplier outages and regulatory delays in cross-border transport.

    2) Choose a manufacturing model that matches isotope half-life

    Different isotopes drive different logistics architectures:

    • Longer-lived isotopes (e.g., Lu-177, Ac-225): may support more centralized radiolabeling and batch release models.
    • Shorter-lived isotopes (e.g., Pb-212 ~10.6 hours): push you toward decentralized generation and local radiolabeling close to the patient.

    In Latin America, this choice should also account for: (1) availability of qualified nuclear medicine infrastructure, (2) cross-border shipping routes, and (3) the maturity of local partners (CDMOs, radiopharmacies, and specialized couriers).

    3) Minimize handoffs: every transfer adds time, risk, and decay

    Radiopharma supply chains can involve multiple players exchanging radioactive intermediates or final products before patient administration. Each handoff introduces:

    • Time loss (and therefore activity loss due to decay)
    • Quality risk (chain-of-custody, temperature and shielding controls, documentation)
    • Regulatory friction (hazmat paperwork, customs timing, transport authorizations)

    Design rule: whenever feasible, reduce the number of handoffs by using more integrated partners or regional hub-and-spoke models that shorten shipping legs and standardize handling.

    4) Make “site readiness” a trial endpoint for operations

    Hospitals and treatment centers play a critical role in final handling, storage, and administration. For radiopharma studies, site readiness is not a checkbox—it’s an operational capability. A practical readiness assessment should include:

    • Receiving procedures: trained staff, radiation safety workflows, and documentation discipline.
    • Storage and shielding: compliant storage conditions, monitoring, and access controls.
    • Administration capability: dosing accuracy, decay-aware scheduling, and incident response plans.
    • Waste management: procedures for radioactive waste and contaminated materials.

    In multi-site Latin America trials, variability in readiness is common. Sponsors should plan to standardize training, templates, and QA checks, and to run an early “dry run” shipment where possible.

    5) Logistics is not an afterthought—write it into the protocol

    Many protocols focus heavily on clinical endpoints and adverse event reporting but leave logistics to operational teams late in the process. A stronger approach is to embed decay-aware operational constraints into the protocol and trial execution plan, such as:

    • Scheduling windows for dosing relative to manufacturing time and transport time.
    • Backup visit procedures if shipments are delayed (including re-dosing rules where appropriate).
    • Defined responsibilities across isotope suppliers, CDMOs, couriers, and sites.

    This reduces protocol deviations and avoids the “logistics-driven” screen failures that can quietly erode trial power.

    6) A practical Latin America framework: regional hubs + local radiolabeling where needed

    One pragmatic way to manage Latin America complexity is a regional hub-and-spoke approach:

    • Hub(s): centralized or regional sites with strong infrastructure for radiolabeling and dose formulation.
    • Spokes: patient-facing treatment sites within predictable transport time windows.

    For very short half-life products, the hub may need to be in-country, or you may need local generators and radiolabeling capability. For longer half-life products, regional hubs can reduce redundancy and still meet dosing schedules.

    FAQ

    What is the single biggest logistics factor in radiopharmaceutical trials?

    Half-life. It drives manufacturing model, transport timing, number of handoffs, and site scheduling constraints.

    Can radiopharmaceutical trials be run across multiple Latin America countries?

    Yes, but the supply chain must be designed explicitly for cross-border transport, regulatory requirements for radioactive materials, and realistic customs timelines.

    Should sponsors build in-house radiolabeling capabilities?

    It depends on scale, isotope type, and strategic priorities. Many sponsors partner with CDMOs and specialized providers to avoid costly infrastructure investments while gaining expertise and established safety systems.

    Bottom line: radiopharmaceutical trials succeed when operations are designed around physics. In Latin America, sponsors who align isotope choice, manufacturing model, handoffs, and site readiness can unlock the region’s speed advantages without compromising safety or data integrity.

  • Brazil’s 90 Day Clinical Trial Clock: A Practical Activation Playbook For First-In-Human Studies

    Brazil’s 90-Day Clinical Trial Clock: A Practical Activation Playbook for First-in-Human Studies

    For MedTech founders and regulatory leaders, Brazil has quietly become one of the most “plannable” countries in Latin America for early-stage clinical activation. A core reason is Brazil’s recent legal and regulatory modernization, which introduced a defined review window and clearer guardrails for starting studies.

    This article translates the change into a sponsor-facing activation playbook: what the 90-business-day clock means, how it interacts with ethics approvals, and what you should build into your timeline to avoid rework. The goal is not to “rush” a trial—it’s to make your activation schedule predictable and audit-ready.

    1) What changed in Brazil (and why it matters for FIH planning)

    Brazil’s Law No. 14.874/2024 established a national system of ethics in research involving humans and introduced a defined 90-business-day review window for ANVISA’s assessment of clinical trial applications that support marketing authorization.

    In practical terms, this is a planning upgrade. Sponsors can build a realistic activation calendar, align manufacturing and logistics windows, and avoid “open-ended” waiting periods that often inflate costs in early-stage programs.

    Importantly, Brazil still requires both ethics approval and ANVISA approval before initiation. However, the rules allow parallel submission so you can run key workstreams concurrently rather than serially.

    2) The activation sequence: ethics, ANVISA, and parallelization

    For most sponsors, the fastest compliant path is a two-track plan:

    • Track A (Ethics): prepare site documents, informed consent, investigator materials, and submit to the local ethics committee process.
    • Track B (Regulatory): prepare the ANVISA dossier and submit in parallel, ensuring your package is consistent with what ethics committees will see.

    A common pitfall is treating ethics and regulatory packages as separate artifacts. Instead, use a single “source of truth” for protocol versioning, risk language, endpoints, and safety reporting workflows.

    3) Don’t miss the hidden gating item: the trial-specific dossier

    Brazil’s process includes a key practical requirement: ANVISA’s technical analysis of the primary petition may depend on the filing of a trial-specific dossier. That means your internal readiness must include not only the umbrella development dossier, but also at least one trial-specific submission with the minimum documentation set.

    Operational takeaway: build your activation plan around “dossier completeness” milestones, not just “submission sent.” Sponsors who plan only to the submission date often discover late-stage gaps in translations, investigational product documentation, or safety reporting alignment.

    4) What “decurso de prazo” means (and what it does NOT mean)

    Brazil’s reforms also created an important concept often summarized as decurso de prazo: if the health authority does not issue a decision within the legal timeline and the study has the required ethics approvals, clinical development can begin.

    For sponsors, this is best treated as a risk-managed backstop rather than a default strategy. Your activation plan should still assume you will operate with an explicit authorization outcome and complete documentation. Use the statutory timeline to reduce uncertainty—not to reduce diligence.

    5) A sponsor-ready 90-day activation checklist

    If you want to benefit from predictable timelines, your internal systems must be “startup-ready” before the clock runs out. Here is a checklist that consistently prevents avoidable delays:

    • Regulatory narrative consistency: protocol synopsis, device/drug description, intended use, and risk statements match across all documents.
    • Import and labeling readiness: confirm investigational supply chain steps, packaging needs, and local labeling conventions early.
    • Safety workflow: clear SAE reporting path, vendor responsibilities, and escalation coverage (including weekends/holidays).
    • Data integrity: eCRF, source templates, and monitoring plan support inspection readiness from Day 1.
    • Site enablement: training plan, delegation logs, and equipment calibration records are not afterthoughts.

    6) How to use Brazil strategically inside a Latin America multi-country plan

    Many early-stage sponsors run a multi-country Latin America strategy to balance speed, cost, and enrollment diversity. Brazil’s clearer timeline can play multiple roles:

    • Anchor country: you plan your “first patient in” forecast around a predictable activation window.
    • Evidence builder: you generate high-quality data to support later reimbursement or regulatory submissions elsewhere.
    • Operational benchmark: you standardize SOPs and monitoring routines that can be replicated across the region.

    The key is harmonization: standardize your core protocol and quality system while adapting country-level workflows (ethics requirements, import pathways, and contracting norms).

    FAQ

    Does Brazil still require ethics approval before starting a clinical trial?

    Yes. Sponsors should plan for both ethics and regulatory authorization and use parallel workstreams to compress time without compromising compliance.

    Is the 90-business-day period a guarantee that my trial will be approved?

    No. It is a defined review window that improves predictability; approval still depends on dossier completeness and meeting regulatory and ethical requirements.

    What is the biggest activation mistake sponsors make in Brazil?

    Underestimating the time to assemble a trial-specific dossier and align all documents (protocol, consent, IP description, safety reporting). “Submitted” does not equal “complete.”

    Bottom line: Brazil’s reform is a planning advantage. Sponsors who pair it with disciplined document control, parallel submission strategy, and site readiness can reduce activation uncertainty—one of the most expensive problems in early-stage trials.

  • A Practical Regulatory Timeline For First-In-Human Medical Device Studies In Latin America (2026)

    A Practical Regulatory Timeline for First-in-Human Medical Device Studies in Latin America (2026)

    For MedTech founders and regulatory directors, Latin America can be the fastest path to a first-in-human (FIH) medical device milestone—if you treat timeline as an operational deliverable, not a hope. The region is not a single market: documentation, ethics review cadence, import steps, and contract mechanics vary by country and by whether your study is observational, non-significant risk (NSR), or significant risk.

    This article provides a practical way to plan an FIH device study timeline across Latin America in 2026: what workstreams to run in parallel, where delays typically occur, and how to de-risk your critical path without compromising compliance or participant safety.

    1) Start with a “workstream map,” not a single Gantt chart

    FIH device studies commonly stall because sponsors build one linear plan when the reality is a set of interdependent workstreams. A useful planning framework separates your launch into seven workstreams, each with its own owners, documents, and review cycles:

    • Protocol package (protocol, IB/IFU, risk analysis, monitoring plan, DSMB plan if needed)
    • Country regulatory submission (device classification/route, authority forms, translations, legalization requirements if any)
    • Ethics approval (central/local IRB/ethics committee workflow, consent language, recruitment materials)
    • Site contracting & budgets (CTA, indemnification, insurance certificates, payment triggers)
    • Import & logistics (shipping lanes, customs broker readiness, temp-control, labeling)
    • Site activation (SIV readiness, staff training, device accountability tools)
    • First patient in (FPI) (screening plan, recruitment levers, backup sites)

    When these workstreams are run deliberately in parallel, many sponsors can compress timelines materially versus the “submit, wait, then do the next thing” approach.

    2) A realistic 2026 timeline template (what to do in each month)

    Every program differs, but for early-feasibility or FIH device studies, a practical timeline template often looks like this:

    • Weeks 0–2: Feasibility + site shortlist. Confirm patient pool, investigator interest, imaging/lab capabilities, and whether your endpoints are standard-of-care in that setting.
    • Weeks 1–4: Submission-ready document set. Build the “country-ready” version of the protocol package: consistent terminology, device description aligned with IFU, and localized consent templates.
    • Weeks 3–8: Parallel ethics + regulatory preparation. Prepare authority-specific forms while the ethics packet is being finalized; do not wait for final contracts to start regulatory readiness.
    • Weeks 6–12: Contracts, budgets, and insurance. In many countries, the slow step is not scientific review but the negotiation of indemnification clauses, invoice rules, and insurance wording.
    • Weeks 8–14: Import and first shipment readiness. Align labeling, airway bills, and broker processes early; confirm whether your device is shipped as commercial goods, samples, or study materials and plan accordingly.
    • Weeks 12–18: SIV + site activation. Execute training, device accountability procedures, and data capture dry runs.
    • Weeks 16–24: FPI window. A strong screening plan and backup sites protect you from “approval achieved, recruitment delayed.”

    Rather than treating “approval” as the finish line, treat it as the midpoint: you still need operational readiness to reach FPI.

    3) Where timelines slip (and how to protect the critical path)

    Across Latin America, recurring delays tend to cluster into a few categories:

    • Translation and document consistency issues. Inconsistencies between protocol, IFU, and consent language trigger rework during ethics review.
    • Contract sequencing mistakes. If you wait for final CTA language before starting budget alignment or insurance certificates, you create avoidable idle time.
    • Import readiness left too late. Even when the device is low-risk, shipments can be rejected if labeling, documentation, or declared values are unclear.
    • Over-reliance on a single site. A single high-performing hospital is not a recruitment strategy; build a backup shortlist early.

    Two simple practices prevent many timeline slips: (1) run a weekly “document control” check to keep all versions synchronized, and (2) hold a pre-import readiness call with your broker and study team before any shipment is booked.

    4) Country selection: choose based on constraints, not hype

    Latin America offers multiple attractive options, but the best country for your FIH study depends on constraints:

    • Need speed? Prioritize clear ethics pathways, experienced investigators, and predictable import lanes for study materials.
    • Need specific patient phenotypes? Choose where that patient population is concentrated and where endpoints align with standard clinical practice.
    • Need imaging or specialized procedures? Ensure site infrastructure and maintenance/QA standards can support your device and endpoints.

    A practical rule: pick the country where your operational bottleneck is easiest to solve. If your bottleneck is import complexity, choose the market where your logistics and broker experience is strongest. If your bottleneck is investigator capability, choose the market with the deepest specialty network.

    FAQ

    • How long does an FIH device study typically take to reach first patient in (FPI) in Latin America?
      Many sponsors plan a 4–6 month window from kick-off to FPI when workstreams run in parallel, but timelines depend on device risk, required reviews, contracting speed, and import readiness.
    • What is the most common avoidable delay?
      Contracting and insurance language misalignment, followed closely by late import readiness and inconsistent translated documents.
    • How can sponsors reduce timeline risk without cutting corners?
      Use a workstream map, keep document versions synchronized, and build redundancy (backup sites, backup shipping lanes, and a recruitment contingency plan).

    Bottom line: In 2026, sponsors that treat Latin America FIH timelines as an integrated regulatory-and-operations program—rather than a single “submission” event—can reach FPI faster and with fewer surprises.

  • Radiopharmaceutical Trials In Latin America: A Logistics Readiness Framework For Sponsors

    Radiopharmaceutical Trials in Latin America: A Logistics Readiness Framework for Sponsors

    Radiopharmaceutical and theranostics programs have accelerated globally, but their clinical execution has a unique constraint: you are not only running a trial — you are running a time-sensitive supply chain. In Latin America, that supply chain can be a competitive advantage when it is planned well, and a critical risk when it is treated as an afterthought.

    This article offers a practical logistics readiness framework for sponsors planning radiopharmaceutical clinical trials in Latin America. The goal is to help clinical and operational leaders identify failure modes early and design a deployment plan that matches the physics, not just the protocol.

    Why radiopharmaceutical logistics is different

    Radiopharmaceutical trials have “hard” operational constraints: isotope half-life, radiation safety controls, qualified hot lab capacity, imaging standardization, and tightly coordinated shipment windows. In addition, sponsors may need to coordinate with multiple stakeholders — manufacturer, radiopharmacy, courier, customs brokers, hospital nuclear medicine teams, and regulators — where each handoff introduces risk.

    Because of these constraints, a strong sponsor question is: Can we execute the chain reliably, repeatedly, and compliantly for every subject?

    A logistics readiness framework (4 pillars)

    Use the following four pillars to assess readiness before site activation.

    Pillar 1: Isotope supply and contingency planning

    • Primary supply route: Define the manufacturing source, batch release timing, and shipment windows that match enrollment cadence.
    • Secondary route: Identify a backup route for disruptions (transport restrictions, manufacturing delays, flight changes).
    • Buffer strategy: For short half-life isotopes, “buffer” often means operational flexibility (multiple shipment windows) rather than inventory.

    Pillar 2: Regulatory and permit architecture

    • Import permits and documentation: Confirm what must be approved before the first shipment, and what can be handled per-shipment.
    • Labeling and chain-of-custody: Ensure labels, documentation, and custody logs satisfy both radiation safety and clinical trial requirements.
    • Waste and radiation safety: Map disposal pathways and responsibilities with each site to avoid last-minute operational blocks.

    Pillar 3: Site infrastructure and workflow maturity

    • Hot lab capability: Validate equipment, personnel qualification, and SOPs for receipt, preparation, and administration.
    • Scheduling discipline: Radiopharmaceutical administration is scheduling-sensitive. Sites need reliable slot control and patient preparedness workflows.
    • Adverse event readiness: Ensure emergency procedures and escalation pathways are documented and rehearsed.

    Pillar 4: Imaging, dosimetry, and data standardization

    • Imaging protocol consistency: Standardize acquisition parameters and timing relative to administration.
    • Calibration and QA: Establish calibration schedules and quality checks to reduce inter-site variability.
    • Data transfer and review: Define secure transfer pathways, central reads (if used), and turnaround expectations.

    Common failure modes — and how to prevent them

    • Enrollment outpaces supply planning: Align recruitment targets to realistic shipment cadence and site throughput.
    • Customs and documentation surprises: Create country-specific shipment playbooks and run a “first shipment rehearsal.”
    • Inconsistent imaging: Use standardized checklists and training, and consider centralized QA early.
    • Site capability overestimation: Validate the workflow in practice, not only on paper. A site can be clinically excellent and still operationally unready for radiopharmaceutical constraints.

    FAQ

    1) What should we assess first when choosing Latin American countries for radiopharmaceutical trials?
    Start with isotope availability routes, hot lab capacity, and the country’s ability to support compliant import and radiation safety workflows. If those are weak, other advantages will not compensate.

    2) Are logistics risks higher in Latin America than in the U.S. or EU?
    They are different. Risks often relate to cross-border shipment orchestration and variability in infrastructure by site. With the right planning and experienced operators, sponsors can build reliable execution pathways.

    3) How do we prevent schedule failures due to isotope half-life constraints?
    Design your operational plan around the isotope clock: confirmed shipment windows, controlled scheduling, backup routes, and rapid communication workflows across all parties.

    Bottom line: Radiopharmaceutical clinical trials reward operational maturity. Sponsors that treat logistics as a core part of trial design — not a downstream task — can unlock faster, more reliable execution across Latin America.

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, which is already operative at 62 calendar days under Disposición 7516/25, is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (62-day pathway, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost (USD 15,000 to 35,000 per patient versus USD 40,000 to 75,000 in the U.S. and Europe) and regulator throughput (62 days under 7516/25 versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols on the Disposición 7516/25 parallel-review pathway. The 62-day timeline allows a 2026 Q3 site selection to produce first-patient-in by year-end. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Radiopharmaceutical Trials In Latin America: A Practical Logistics Playbook For Short‑Lived Isotopes

    Radiopharmaceutical Trials in Latin America: A Practical Logistics Playbook for Short‑Lived Isotopes

    Radiopharmaceutical trials are a different operational species. The science may be the differentiator, but logistics is the constraint: short half-lives, radiation safety requirements, time-sensitive patient scheduling, and multi-agency approvals for cross-border movement. Sponsors who treat radiopharma like a conventional IMP supply chain often learn the hard way—through missed dosing windows and unusable shipments.

    1) Start with the physics: half-life turns every delay into lost dose

    If your isotope decays in hours, you don’t have “shipping delays”—you have immediate product shrinkage. The planning unit is not days; it is minutes. That means your protocol and operations plan must specify allowable time windows for production, release testing, transport, and administration, and it must include decision rules for when to cancel, reschedule, or reroute.

    • Define the decay budget: the maximum elapsed time from end of synthesis to administration.
    • Map critical control points: handoffs where delays occur (release, airport acceptance, customs, last-mile, site receiving).
    • Build a “go/no-go” clock: so everyone knows when continuing becomes scientifically meaningless.

    2) Cross-border execution in Latin America: permits, airports, and handoffs

    In many Latin America routes, the main risk is not distance—it is variability: airline handling, airport screening queues, and country-by-country documentation requirements. The most reliable programs treat each shipment like a rehearsed procedure rather than an ad hoc package drop.

    Internal execution experience across the region repeatedly highlights that reliability improves when sponsors standardize these elements:

    • Packaging qualification: validated temperature/containment performance and clear labeling for every handler.
    • Documentation kit: standardized set of shipping papers, permits, and emergency contacts—pre-reviewed by local experts.
    • Chain of custody: timestamped handoffs with escalation triggers.
    • Site receiving SOP: pre-briefed staff, equipment readiness, and immediate QC/receipt checks.

    3) Site readiness: the hidden bottleneck

    Even a perfect shipment fails if the site is not ready. A radiopharma site must coordinate pharmacy/nuclear medicine teams, imaging, patient prep, and administration windows. The sponsor’s job is to make this coordination easy and repeatable.

    Recommended site readiness checklist:

    • Weekly capacity confirmation: confirm patient slots, staff coverage, and scanner availability.
    • Receiving drill: simulate the shipment arrival, handoff, and documentation review.
    • Waste and incident plan: clear procedures for contamination, spills, and disposal aligned with local requirements.
    • Back-up scheduling: a pre-identified alternative window when a shipment is delayed but still usable.

    4) Resilience without runaway cost: design a tiered contingency plan

    Not every shipment needs the most expensive option. Create a tiered plan:

    • Tier 1 (default): primary carrier + primary route, with standard packaging and standard site workflow.
    • Tier 2 (moderate disruption): alternate flight routings and a backup last-mile provider.
    • Tier 3 (critical disruption): rapid escalation options, including premium routing and emergency re-release windows.

    This structure helps you maintain reliability while containing cost—and it makes decision-making faster in the moment.

    FAQ

    Why is radiopharma logistics harder than standard drug trials?
    Because many isotopes decay quickly, small delays in production, packaging, flight connections, or site preparation can reduce delivered activity and impact dosing windows.

    What is the most common operational failure mode?
    Misaligned schedules across cyclotron/production, export/import clearances, airport handling, last-mile transport, and site readiness—creating avoidable holds that consume half-life.

    How do sponsors add resilience without exploding cost?
    Use a tiered contingency plan: alternate flight routings, backup depots, standardized packaging, qualified second-source carriers, and rehearsed site receiving checklists; reserve higher-cost options only for critical shipments.

    Need help executing radiopharma studies in Latin America? bioaccess® supports sponsors with regional operational planning, site activation support, and logistics coordination built for time-sensitive programs.

  • Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil continues to be one of the most important anchors for early-stage clinical development in Latin America, but the compliance baseline is moving. In 2026, Anvisa highlighted that Brazil’s clinical research environment has been updated through Law No. 14.874/2024 (ethical aspects of research with human beings) and the newer regulatory package RDC 945/2024 plus IN 338/2024 for clinical research supporting registration of medicines, which Anvisa notes took effect in early 2025 (Anvisa).

    For MedTech founders and regulatory directors planning first-in-human (FIH) or early pivotal work in the region, the strategic opportunity remains: access to experienced investigators, high-quality sites, and diverse patient populations. The operational requirement, however, is to design submissions, vendor oversight, and essential documentation so you can demonstrate control at any moment—especially as inspection programs mature.

    1) What changed in Brazil’s research governance—and why it matters for sponsors

    Anvisa’s 2025 activity reporting explicitly connects the new ethical law and the updated clinical research regulation to the agency’s current oversight approach (Anvisa). In parallel, Anvisa’s inspection metrics reporting emphasizes inspection readiness against GCP expectations (ICH E6 (R2) or updates) while referencing RDC 945/2024 and Law 14.874/2024 as part of the inspection framework (Anvisa).

    Practical takeaway: even when timelines are competitive, sponsors should assume that documentation quality, vendor governance, and data integrity controls will be evaluated more explicitly. This is good news for well-prepared early-stage teams: strong fundamentals can shorten back-and-forth with sites and reduce downstream remediation.

    2) A sponsor-ready timeline: how to think about “FIH speed” without compliance debt

    Internal execution experience across Latin American programs repeatedly shows that speed usually breaks down in predictable places: incomplete essential documents, misaligned responsibilities between sponsor and CRO, and late-stage changes to protocol and informed consent artifacts. Treat “speed” as a systems outcome rather than a hero effort.

    • Pre-submission (4–8 weeks): lock protocol operational feasibility, confirm investigational product/device logistics, and establish a document control plan.
    • Submission-ready package: create a single source of truth for protocol, IB/IFU (as applicable), safety reporting plan, and data handling plan.
    • Site activation: standardize training, delegation, and vendor onboarding so the first site is not a one-off build.

    Many startups underestimate that “time to first patient” is often constrained by operational readiness, not just authority review. Investing early in a repeatable activation model is one of the highest ROI moves you can make.

    3) Inspection readiness: build once, benefit for years

    Anvisa’s inspection metrics report notes its focus on inspections conducted in 2024 and 2025 and positions inspections as a tool to protect participants and data integrity (Anvisa). For early-stage sponsors, the implication is clear: build inspection readiness into your operating rhythm rather than treating it as a “phase 3 problem.”

    Start with five non-negotiables:

    • Essential document discipline: version control, signatures, and clear ownership.
    • Delegation and training: role-based training mapped to tasks; keep it auditable.
    • Deviation and CAPA workflow: define severity levels and timelines; trend issues.
    • Vendor oversight: documented qualification, KPIs, and periodic review for CROs, labs, and logistics partners.
    • Data integrity: audit trails, access controls, and reconciliation between source, eCRF, and safety database.

    4) How to operationalize this across Latin America (not just Brazil)

    Brazil is rarely the only country in a Latin America strategy. Use Brazil as the quality anchor and replicate the same operating system across additional countries. You can localize what must be localized (ethics committee formats, language, import processes), while keeping your core compliance artifacts stable.

    A useful mental model: create a regional master file (core documents, SOPs, training), plus country modules (local submissions, contracts, import permits), plus site modules (delegation, logs, training, monitoring).

    FAQ

    When did Brazil’s latest clinical research regulations take effect?
    Brazil’s updated framework referenced by Anvisa includes Law 14.874/2024 (in force since 29 Aug 2024) and RDC 945/2024 plus IN 338/2024 (effective 2 Jan 2025).

    Do these changes apply to medical devices too?
    The Anvisa updates cited relate to clinical research for registration of medicines and biologics; device sponsors should still align operational quality systems and inspection readiness to ICH GCP expectations and local ethics requirements.

    How should startups prepare for inspection readiness?
    Build inspection-ready documentation from day one: role-based training, version-controlled essential documents, delegation logs, deviation management, and vendor oversight that can be demonstrated quickly.

    Need help designing a Latin America FIH plan? bioaccess® supports sponsors with regional feasibility, activation, and execution strategies built for speed and inspection readiness.

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), caps clinical trial protocol authorization at 62 calendar days (45 working days maximum). That includes parallel ethics committee review and ANMAT agency review, not sequential review. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled. Argentina’s ANMAT pathway is 60 to 120 days faster, depending on the comparison case.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    Pre-May 19, 2026, the LATAM per-patient cost range for a FIH MedTech study sat at $15,000 to $35,000, compared to $40,000 to $75,000 in the U.S. and Europe. For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25, the 62-day pathway, the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol under Disposición 7516/25 will, in a typical case, have ANMAT approval and first-patient-in achieved before the FDA has finished its initial IDE review. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a 62-day pathway into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. The 62-day pathway under Disposición 7516/25 is operative. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • First-In-Human In Brazil In 2026: A Practical Timeline For Sponsors

    First-in-Human in Brazil in 2026: A Practical Timeline for Sponsors

    Primary keyword: first-in-human trial Brazil timeline

    Brazil is increasingly on the shortlist for early-stage clinical development because sponsors can combine a large patient base with growing regulatory clarity. A recent policy analysis argued that Lei 14.874 de 2024 created the basis for a more predictable environment and, for the first time, establishes timelines and greater regulatory clarity for clinical studies.

    This article gives a practical, sponsor-side timeline for launching a first-in-human (FIH) study in Brazil in 2026—what to do first, what typically slows teams down, and how to sequence work so you do not lose weeks to preventable back-and-forth.

    1) Define the “Brazil-ready” FIH package (Weeks 0–2)

    Before any submission, align internal stakeholders on what “Brazil-ready” means. For most MedTech and biopharma sponsors, FIH readiness is not only a protocol question—it is also a documentation and site execution question.

    • Protocol and IB alignment: Ensure endpoints, safety monitoring, and dose-escalation logic are consistent with your global plan.
    • Country adaptations: Identify what must be localized or supplemented (consent language, site materials, labeling, and investigator documentation).
    • Feasibility assumptions: Confirm whether required imaging, lab, or procedural capabilities exist at target sites.

    Internal best practice: Create a single “FIH Brazil master checklist” with owners and due dates. Treat it as a deliverable, not an afterthought.

    2) Select sites for speed, not just prestige (Weeks 1–4)

    In FIH, startup speed is highly correlated with site readiness. Sponsors often choose sites based on reputation, then discover contracting and operational realities late.

    • Prioritize operational maturity: Look for sites with dedicated research staff, established ethics processes, and experience with sponsor audits.
    • Validate recruitment pathways: Treatment-naive populations can be an advantage, but referral networks still matter.
    • Assess import and handling constraints: If your study uses temperature-sensitive materials, confirm storage and chain-of-custody procedures early.

    3) Build a parallel workstream plan (Weeks 2–6)

    The most common timeline mistake is running tasks sequentially that can be executed in parallel. Even when formal review clocks improve, sequential execution can erase the benefit.

    To compress time, run these workstreams at the same time:

    • Regulatory dossier preparation (quality, safety documentation, and trial authorization package)
    • Ethics submission package (site-specific documents and consent)
    • Contracts and budgets (CTA, indemnities, payment schedules, and monitoring model)
    • Supply and logistics readiness (import planning, labeling, storage validation, and back-up scenarios)

    Even when legal reforms aim to improve predictability, sponsors still need coordinated execution across stakeholders to realize those gains.

    4) Anticipate “hidden” startup time: contracts, import, and training (Weeks 4–10)

    Even when review timelines are favorable, sponsors can lose time after approvals due to operational bottlenecks:

    • Contract negotiation cycles: Build buffer time for legal review, redlines, and institutional sign-off.
    • Import and release: If your investigational product or device must be imported, confirm lead times and documentation requirements early.
    • Site initiation and training: FIH trials require strict adherence to safety procedures; schedule training sessions while approvals are in progress.

    Practical tip: Maintain a “go-live readiness dashboard” that tracks contract status, shipment readiness, and training completion. This prevents surprises when the green light arrives.

    5) A sponsor-friendly 2026 FIH timeline (example)

    Every program is different, but a realistic planning template looks like this:

    • Weeks 0–2: Brazil-ready protocol package, checklist, and internal alignment
    • Weeks 1–4: Site selection, feasibility, and early budget/CTA drafts
    • Weeks 2–6: Parallel dossier + ethics package finalization
    • Weeks 4–10: Contracts, import planning, training, and vendor setup
    • Weeks 10–14: Final site activation steps and first-patient readiness

    If you are aiming for speed, measure time-to-ready as rigorously as you measure time-to-approval. In many FIH programs, the fastest sponsors are simply the ones that avoid rework.

    FAQ: First-in-human trial Brazil timeline

    • How long does it take to start a first-in-human trial in Brazil?
      Timelines vary by protocol complexity and site readiness, but sponsors should plan for parallel regulatory and ethics pathways, early document localization, and realistic contracting and import lead times.
    • What is the biggest cause of FIH delays in Brazil?
      In practice, delays often come from incomplete documentation, late site selection, and underestimated startup logistics (contracts, import permits, and investigational product readiness), not just the formal review clock.
    • Can Brazil FIH data support US or EU submissions?
      Yes, when the trial is designed to international GCP standards and endpoints align with your global regulatory strategy, Brazilian data can be part of a broader evidence package.

    Need help planning an FIH startup in Brazil or across Latin America? bioaccess® supports sponsors with country startup planning, site activation, and operational execution—without exposing confidential details publicly.

  • Radiopharma Trials In Latin America: Designing Operations For 6 Hour Half-Lives

    Radiopharma Trials in Latin America: Designing Operations for 6-Hour Half-Lives

    Primary keyword: radiopharmaceutical clinical trial logistics Latin America

    Radiopharmaceuticals are one of the most promising frontiers in oncology, but they force clinical teams to operate on a different clock. An industry announcement noted that because these materials decay in hours rather than months, the operational window for patient administration is extremely narrow, leaving very little margin for error.

    Latin America can be an attractive region for radiopharma development, but sponsors need an operating model that is designed for short half-lives, just-in-time supply, and site readiness. This article outlines a practical framework for radiopharmaceutical clinical trial logistics in Latin America—without duplicating country-specific checklists already covered elsewhere.

    1) Start with the “decay clock” and design backward

    Radiopharma operations should start with physics. If a product’s usable window is measured in hours, then every downstream step must be planned backwards from the scheduled administration time:

    • Manufacturing slot and release testing (including potential rework)
    • Packaging and validated temperature control
    • Transportation and customs risk (for cross-border moves)
    • Site receipt, verification, and patient preparation

    Operational principle: Do not treat shipment as a “logistics problem.” Treat it as part of the dosing procedure.

    2) Build site readiness around minute-by-minute workflows

    In many conventional trials, small workflow inefficiencies are tolerated. In radiopharma, they can cause missed windows or protocol deviations.

    • Define a standard receiving workflow: who signs, where it is stored, and how identity and activity are verified.
    • Train for exceptions: delayed flights, partial shipments, or last-minute patient rescheduling.
    • Synchronize departments: nuclear medicine, pharmacy, imaging, and the clinical team must share one operational plan.

    3) Manage supply risk with redundancy and “plan B” lanes

    A radiopharma webinar announcement highlighted just-in-time manufacturing and strict cold-chain requirements as differentiators from standard investigational products, and emphasized that protocol pivots and supply disruptions are expected rather than rare. In Latin America, the right mitigation strategies can include:

    • Backup transport lanes: pre-qualified couriers and alternate airport routing options.
    • Site network design: cluster sites to reduce travel time from production to administration.
    • Inventory philosophy: you cannot “stockpile” short half-life product, so redundancy must come from operations, not storage.

    4) A practical operating model for Latin America radiopharma programs

    To make logistics predictable, sponsors can standardize four elements across countries:

    • Readiness checklists: site staffing, equipment calibration, temperature monitoring, and emergency procedures.
    • Scheduling discipline: patient scheduling should be tied to confirmed manufacturing slots and transport windows.
    • Visibility: live tracking of manufacturing status, shipment milestones, and site receipt confirmation.
    • Contingency triggers: pre-defined thresholds for when to reschedule a patient, re-route a shipment, or activate an alternate site.

    When these elements are standardized, the operational advantage of Latin America—experienced research sites and growing infrastructure—can translate into reliable execution, not just theoretical speed.

    5) Data integrity and chain-of-custody: treat the dose as a specimen

    With radiopharmaceuticals, sponsors should document the product journey with the same rigor used for biospecimens. This reduces deviations and supports inspection readiness.

    • Time-stamped handoffs: manufacturing release, courier pickup, arrival at site, and administration time.
    • Temperature and shielding logs: continuous monitoring, out-of-range triggers, and documented corrective actions.
    • Identity checks: verify patient, product label, and activity at the moment of administration.

    Practical tip: Create a single-page “dose administration record” that sites can complete in real time and upload the same day.

    6) Regulatory and customs planning: design for border reality

    Latin America is not one regulatory system. Cross-border moves can introduce unpredictable delays, so logistics planning should assume variability and reduce exposure wherever possible.

    • Prefer in-country or near-country production when feasible: shorter transit times reduce decay loss.
    • Pre-clear documentation: align on import documentation, labeling, and receiver information well before first shipment.
    • Schedule around local constraints: weekends, holidays, and airport cutoffs matter more when the product lifetime is measured in hours.

    When sponsors plan for these constraints, Latin America sites can deliver high-quality execution even for time-sensitive protocols.

    FAQ: Radiopharmaceutical clinical trial logistics Latin America

    • Why are radiopharmaceutical trials harder to run than conventional trials?
      Because many products decay in hours, the operational window is extremely narrow and sites must coordinate manufacturing, shipping, and patient readiness with little margin for error.
    • What is the most common operational failure mode?
      Missed administration windows caused by delays in manufacturing release, transportation, site workflow issues, or patient no-shows.
    • How can Latin America sites reduce missed dosing windows?
      By building standardized readiness checklists, aligning patient scheduling with shipment timelines, and designing contingency plans for transportation or manufacturing disruptions.

    Planning a radiopharma study in Latin America? bioaccess® can help sponsors design site networks, readiness plans, and startup execution models that reduce missed dosing windows.